Buprenorphine and its formulations : a comprehensive review
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Health psychology research - 10(2022), 3 vom: 20., Seite 37517 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poliwoda, Salomon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesic |
|---|
| Anmerkungen: |
Date Revised 26.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.52965/001c.37517 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345184491 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345184491 | ||
| 003 | DE-627 | ||
| 005 | 20231226024505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.52965/001c.37517 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345184491 | ||
| 035 | |a (NLM)35999975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poliwoda, Salomon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Buprenorphine and its formulations |b a comprehensive review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Buprenoprhine | |
| 650 | 4 | |a analgesic | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a partial agonist | |
| 650 | 4 | |a substance abuse | |
| 700 | 1 | |a Noor, Nazir |e verfasserin |4 aut | |
| 700 | 1 | |a Jenkins, Jack S |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Cain W |e verfasserin |4 aut | |
| 700 | 1 | |a Steib, Mattie |e verfasserin |4 aut | |
| 700 | 1 | |a Hasoon, Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Varrassi, Giustino |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health psychology research |d 2013 |g 10(2022), 3 vom: 20., Seite 37517 |w (DE-627)NLM243870574 |x 2420-8124 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:3 |g day:20 |g pages:37517 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.52965/001c.37517 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 3 |b 20 |h 37517 | ||